Literature DB >> 9770424

Characterization of mRNA for hepatitis delta antigen: exclusion of the full-length antigenomic RNA as an mRNA.

K Lo1, S B Hwang, R Duncan, M Trousdale, M M Lai.   

Abstract

Hepatitis delta virus (HDV) encodes a single protein, the hepatitis delta antigen (HDAg), which is thought to be translated from a 0. 8-kb RNA of antigenomic sense. This subgenomic RNA species is present in very small amounts in HDV-infected liver tissues and in cultured cells infected or transfected with HDV, and in some cases it cannot be detected at all. In contrast, HDAg protein is present in large amounts in all natural and experimental models of HDV infection. This study addresses whether other HDV RNA species, such as the antigenomic-sense, genome-size HDV RNA can also serve as the mRNA for HDAg synthesis. Taking advantage of the ability of herpes simplex virus (HSV) to degrade only polyadenylated mRNAs, we examined the effect of HSV coinfection on HDAg synthesis. It was shown that HSV infection did degrade the subgenomic 0.8-kb HDV mRNA but not HDV genome-length RNA. Under such conditions, HDAg synthesis was completely inhibited. Furthermore, the genome-length HDV RNA was found not to be associated with polysomes. Finally, in vitro translation studies demonstrated that HDAg could not be translated directly from the genome-length antigenomic-sense HDV RNA. These results suggest that only the subgenomic RNA species of HDV possesses properties characteristic of the mRNA for HDAg and that the genome-length RNA cannot be used for translating HDAg. In addition, we found that HDV RNA replication did not depend on de novo HDAg synthesis. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9770424     DOI: 10.1006/viro.1998.9364

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Efficient site-specific nonribozyme opening of hepatitis delta virus genomic RNA in infected livers.

Authors:  J Chang; G Moraleda; S Gudima; J Taylor
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  RNA-Dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases.

Authors:  L E Modahl; T B Macnaughton; N Zhu; D L Johnson; M M Lai
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 3.  RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus.

Authors:  Michael M C Lai
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

4.  The large delta antigen of hepatitis delta virus potently inhibits genomic but not antigenomic RNA synthesis: a mechanism enabling initiation of viral replication.

Authors:  L E Modahl; M M Lai
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  Origin of hepatitis delta virus mRNA.

Authors:  S Gudima; S Y Wu; C M Chiang; G Moraleda; J Taylor
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

Review 6.  Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.

Authors:  Florian A Lempp; Yi Ni; Stephan Urban
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-08-18       Impact factor: 46.802

7.  Hepatitis Delta Antigen Regulates mRNA and Antigenome RNA Levels during Hepatitis Delta Virus Replication.

Authors:  Kaneemozhe Harichandran; Yiran Shen; Susannah Stephenson Tsoris; See-Chi Lee; John L Casey
Journal:  J Virol       Date:  2019-04-03       Impact factor: 5.103

8.  Identification and characterization of novel small-molecule inhibitors against hepatitis delta virus replication by using docking strategies.

Authors:  Sarita Singh; Sunil Kumar Gupta; Anuradha Nischal; Sanjay Khattri; Rajendra Nath; Kamlesh Kumar Pant; Prahlad Kishore Seth
Journal:  Hepat Mon       Date:  2011-10       Impact factor: 0.660

Review 9.  Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen.

Authors:  Florian A Lempp; Stephan Urban
Journal:  Viruses       Date:  2017-07-04       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.